BioInnovation Institute backs 17 early-stage startups with €9.5M

The BioInnovation Institute (BII) has allocated €9.52 million in convertible loans to 17 early-stage research-based startups. These startups were selected for its Venture Programme, which aims to help them transform research and early-stage technologies into commercially viable businesses. Each company receives a €560,000 convertible loan and access to BII's innovation platform and support network.

The latest cohort joins the institute's growing portfolio of supported startups, which now totals over 140 companies. The 17 companies are developing technologies across healthcare, biotechnology, climate, and other research-driven fields. BII plans to expand its activities across Denmark and Europe, with a goal of supporting 20 to 30 startups annually.

The institute's longer-term aim is to help emerging technologies progress from research towards commercial applications and internationally scalable companies. BII's Chief Business Officer, Trine Bartholdy, emphasized the importance of turning advanced research into scalable businesses and the complex process involved in achieving this goal.

The institute will provide participating companies with access to laboratory infrastructure and a network of entrepreneurs, experts, partners, and investors.